Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If I were the CEO of AbbVie, I'd rather buy ILNS for $ 1 billion and not pay $ 100 million milestone only for OX1 (Fredreich ataxia) ...
Abbvie bought Shire ...
(Reuters) - London-listed drugmaker Shire Plc (SHP.L) succumbed to an increased 31 billion pounds ($53 billion) takeover offer from Abbvie Inc ABBN.N on Monday, signaling the conclusion to a long-running courtship largely motivated by tax.
Shire said it was ready to recommend the deal, the latest in a list of mergers proposed by U.S. firms seeking to cut their tax rates, and which comes less than seven weeks after the collapse of Pfizer Inc's (PFE.N) $118 billion bid for AstraZeneca Plc (AZN.L), also motivated in part by tax factors.
Chicago-based AbbVie, which wants to buy Shire to cut its tax bill and diversify its product line-up, increased its offer to 53.20 pounds per share on Sunday, following a request from the Dublin-based group which had rejected four previous bids.
Citing people familiar with the matter, Reuters had reported on Saturday that Shire, a maker of drugs for rare diseases, had asked AbbVie to sweeten its offer to near 53 pounds per share in order for it to recommend the deal.
Shire said the new bid comprised 24.44 pounds in cash and 0.8960 new AbbVie shares for each Shire share and would result in Shire investors owning around 25 percent of the combined entity.
"The proposed offer seems a fair price that represents good value for both companies’ shareholders," said Mick Cooper, an analyst at Edison Investment Research. Shares in Shire, founded in 1986, hit a record high of 50.45 pounds in mid-morning trading.
AbbVie is eager to buy Shire both to reduce its U.S. tax bill by moving its tax base to Britain - a tactic known as inversion - and to diversify its drug portfolio.
The U.S. group gets nearly 60 percent of its revenue from rheumatoid arthritis drug Humira, the world's top-selling medicine, which loses U.S. patent protection in late 2016.
Analysts at Barclays estimated the move would provide an estimated $1.3 billion tax savings by 2020, reflecting lower UK corporate tax rates.
TAX SAVINGS
AbbVie has proposed creating a new U.S.-listed holding company with a tax domicile in Britain, whose corporate tax rate is set to drop as low as 20 percent from 2015, well below the U.S. headline rate of 35 percent plus local taxes. The UK government has also introduced tax breaks designed to encourage research and development.
"We expect the majority of the tax savings to be realized within the first two years," Barclays analysts said.
"Strategically AbbVie acquires Shire's quality growth assets in platforms including rare diseases, neuroscience and ophthalmology, easing investor concerns about over-reliance on Humira and offering future growth opportunities."
Analyst Alistair Campbell at banking group Berenberg said there were few other British pharmaceutical companies that would suit a tax inversion takeover.
"The company has to be of a certain size, because around 20 percent of the shareholders post deal must be shareholders in the target company, so you can't go for small companies," he said. "Glaxo (GSK.L) is too big, Astra has had an approach from Pfizer and Shire has now gone."
Smith & Nephew Plc (SN.L), Europe's largest maker of artificial joints, has been seen as a possible contender, with U.S.-based Stryker Corp (SYK.N) forced to say it would not bid for the group after reports linking it with a deal circulated in May.
Sweden's Meda AB (MEDAa.ST) rejected an improved takeover offer from U.S. generics firm Mylan Inc (MYL.O) in April, which could have helped reduce taxes.
The approach for Shire, founded in Britain, has been far less controversial than the move for AstraZeneca. Headquartered in Dublin, it is managed from Boston, Massachusetts, and has most of its sales in the United States, resulting in a relatively small business footprint in Britain.
Shire Chief Executive Flemming Ornskov had said he was happy for the company to be sold at the right price, but like AstraZeneca in its defense against Pfizer, he had set out a detailed case as to why it was worth a lot more than AbbVie was originally offering.
($1 = 0.5877 British Pounds)
http://www.reuters.com/article/2014/07/14/us-shire-abbvie-idUSKBN0FJ0ET20140714
.,
I bought ILNS shares because I believed on Bapineuzumab phase 3, and I lost ACAD's takeoff in the past 3 years ( by $ 0.7 to $ 20 and more ) ...
Now, I believe that takeoff of ILNS will be much better on the next years ...
Unfortunately, I think 99% of ILNS's shareholders will sell at first gain of 5 or 10 times !
Only 1% shareholders will sell with gain of 1.000% or 10.000% all shares owned ...
Need strong heart !
Soon TAKEOFF as letter J on graphic !
.,
OX1- Intellect's intellectual property rights:
- Before property of ViroPharma
- Now property of Shire Pharma
- Soon property of AbbVie Pharma
Who will pay?
.,
OX1
http://clinicaltrials.gov/ct2/results?term=OX1&Search=Search
Moreover, trial record 6 and 7 Has Results
---------------------------------
NEW YORK, Sept. 30, 2011 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS) announced today that Intellect has granted an exclusive License to ViroPharma Incorporated (Nasdaq:VPHM) regarding certain of Intellect's licensed patents and patent applications related to Intellect's clinical stage drug candidate, OX1, a multimodal, metal-binding, extremely potent antioxidant molecule, which has been demonstrated to protect nerve cells from highly oxidizing neurotoxins. ViroPharma plans to develop and commercialize OX1 as a treatment of Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
Under the terms of the Exclusive License Agreement, Intellect has agreed to transfer to ViroPharma all of Intellect's intellectual property rights, data and know-how related to its OX1 research and development program. In return, ViroPharma has agreed to pay a $6.5 million up-front licensing fee and will pay additional milestones based upon defined events. The maximum of these milestone payments assuming successful advancement to market could amount to $120 million. In addition, ViroPharma will pay a tiered royalty of up to a maximum of low double digits based on annual net sales.
Intellect recently announced completion of Phase 1 clinical trials for OX1. Dr. Daniel Chain, Intellect's Chairman and CEO, has played a leadership role in the development of OX1 since its therapeutic potential was originally discovered by scientists at NYU Medical School and University of South Alabama in the late 1990s. The universities, which own certain patents in relation to OX1, are entitled to a portion of revenues received by Intellect from any sale or license of OX1 pursuant to an exclusive license agreement between Intellect Neurosciences and the universities.
Dr. Chain commented: "We are pleased to enter into a strategic relationship with ViroPharma, which has ample resources, drug development capabilities and orphan drug marketing expertise to accelerate the development and commercialization of OX1. This transaction is the first for Intellect related to an internally developed compound. It is consistent with our business strategy to create high value assets that can generate revenues to support further development of drugs for the ultimate benefit of patients in desperate need of novel treatments for life-threatening conditions."
About OX1
OX1 is a multimodal antioxidant molecule noted for its potent free radical scavenging activity, metal-binding activity and activation of mitochondria which are responsible for energy production in cells. In addition, OX1 has been tested in numerous different models of neurodegenerative diseases and shown to protect nerve cells from highly oxidizing stimuli caused by metals and other neurotoxins. OX1 has been tested for safety across species and found to be safe and well tolerated in human phase 1 clinical trials. It is administered as a powder in capsules for oral ingestion and is rapidly absorbed by the body.
.,
CHF-5074 has changed its name, now called CSP-1103
See website CereSpir, recently updated:
http://www.cerespir.com/index.htm
It 's very strange and anomalous this recent change ...
Also from "ClinicalTrial.gov" shows that CSP 1103 is sponsored by Grifols Biologicals, Inc., is in phase 3, but for a different study ...
http://clinicaltrials.gov/ct2/show/NCT01731938?term=CSP+1103&rank=1
Coincidentally, Grifols Biologicals Inc. is also conducting a study for Alzheimer's Disease, appointed AMBAR, in phase 2/3 ...
http://clinicaltrials.gov/ct2/show/NCT01561053?term=Grifols+Biologicals+Inc.&rank=9
----------------------------------------------------------
I think when CereSpir was born there was a backroom deal with ILNS ...
I believe that future of ILNS is linked to CereSpir ...
.,
If it is true, we are all happy!
I did not understand how you can to say for sure:
1) By end of next week we have a partnership.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104169655
2) This is not a rumor. Expect something before the hearing coming up on the 22 of July.
3) Why is it before and is it not after 22 July?
Thanks
.,
If it is true, we are all happy!
I did not understand how you can to say for sure:
1) By end of next week we have a partnership.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104169655
2) This is not a rumor. Expect something before the hearing coming up on the 22 of July.
3) Why it is before and it is not after 22 July?
Thanks
.,
... Dr. Frost seeks out fledgling industries that he believes have large growth potential. The fledgling nature of these industries results in a general market undervaluation of their constituent companies, the undervaluation in which Frost’s value lies. ...
http://www.gurufocus.com/news/245013/billionaire-investor-dr-phillip-frost-believes-izea-is-undervalued
.
I feeling that there will be 2 more referrals.
The first adjournment to September and then subsequently to October 2014 ...
This to allow Pfizer to arrive at the completion of phase 2 ...
( Estimate Study Completion Date: October 2014 ) See:
http://www.clinicaltrials.gov/ct2/show/NCT01821118?term=ponezumab&rank=5
I don't know if there is an agreement between Pfizer's lawyers and Shapiro, with new pretext to postpone ...
.
I hope at least $ 1 or better ... ( without Reverse Split !!! )
Unfortunately, ILNS has been held for too long like a dog tied to a chain ... strong hands!
Surely the chain is going to break and the ferocious dog will tear to pieces those who stand against ...
.
Mr. Snipe, you can find more information on follow link:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=103974378
.
Who will buy, or will pay milestone for Friedreich's Ataxia?
Or, who purchase entirely ILNS?
VP 20629 ( Viro Pharma )
SHP 622 ( Shire Pharma )
AVP ??? ( AbbVie Pharma )
----------------------------------------------------------
03 Jul 2014
Updated Rule 2.10 Announcement
... ABBVIE INC. (“AbbVie”) IN CONNECTION WITH A POSSIBLE OFFER (“Offer”) BY ABBVIE FOR SHIRE. ...
http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=979
----------------------------------------------------
... AbbVie believes a merger of AbbVie and Shire would potentially accelerate growth and profitability by leveraging AbbVie's capabilities and infrastructure to make Shire's pipeline and products more successful than its standalone prospects. AbbVie believes that this merger would result in incremental sustainable leadership positions within high value market segments of significant unmet need, including: immunology, rare diseases, neuroscience, metabolic diseases and liver disease (HCV), as well as multiple emerging oncology programs. ...
http://www.nasdaq.com/article/abbvie-inc-statement-regarding-a-possible-offer-for-shire-plc-20140625-00195
http://www.abbvie.com/index.html
.
All shareholders hoped for a quick result!
From letter of June 20, 2013 addressed to shareholders, shows the Business Strategy:
Engagement of Evli Corporate Finance
Recently we announced that the Board of Directors has engaged Evli Corporate Finance to assist the company with the exploration of strategic alternatives. The Board of Directors is undergoing a strategic review of the feasibility and relative merits of various financial strategies for the company, which may include partnerships, strategic business model alternatives, a sale or other transaction.
---------------------------------------------------
All other BioPharma companies created in few months a partnerships, a strategic business model alternatives, or sale ...
Therefore, exactly an year after the assignment granted to Evli, I believe that it is something that requires more time and effort ... so, that is not a partnerships, a strategic business model alternatives, or sale ...
It is probably OTHER TRANSACTION ...
What takes so long?
.
I hope that everything will work out the best way and in a short time!
Shareholders are tired and drifting ... so, I written to Mr. Maza last week!
.
Definitely something great and good is boiling in the pot ...
Mr. Maza has read all the emails of shareholders, however in recent months he does not read anything!
(And of course does not answer).
I am convinced that it is imminent great news, I cannot believe that Mr. Maza has left shareholders and that Evli worked for a year to no avail ...
As for the judge's ruling, ILNS could receive several million dollars ...
Unfortunately, the problem is ... WHEN?
Pfizer will definitely appeal and will spend many years ...
.
From Yahoo message board:
Increased holdings!
Stock Genie Group added and upgraded the stock before court verdict!
We should see lots more volume this week!
http://finance.yahoo.com/mbview/threadview/?&bn=faee84cc-9764-3fc4-b8fc-3d0136af263c&tid=1403529848402-1778ee8a-d2a2-4a06-ab19-688c13f61800&tls=la%2Cd%2C0%2C3
------------------------------------------------------------------
Stock Genie Group
http://www.stockgeniegroup.com/
.
Happy Anniversary to all shareholders!
A year without information or updates ...
Jun 20 2013, 9:25 AM EDT Intellect Neurosciences, Inc. Issues Letter to Shareholders
I sent an email to Mr. Maza for commemorate the anniversary!
Unfortunately, I did not receive any reply ...
I think he is tired to reply: SOON, SOON, SOON, ...
Probably, the silence means imminent "SOON" or very delayed "SOON" ...
Definitely it is not "SOON" !
.
If judge Oing (or wife) bought shares ILNS, it is a good sign ..!
Can somebody verify if he is owner of shares?
.
What mean SOON ( week, month, year, ... ??? )
I just now figured out what it means soon ... a couple of weeks!
We read on this board for many months, SOON, VERY SOON ...
All the reply email from Mr. Maza, always SOON ...
Thanks for the clarity!
I reply to your doubt : When you say approval I assume you mean IDA application for phase III.
---------------------------------------------------------------
No, I meant to say accelerated approval for Phase II.
Accelerated approval: there is no absolute FDA requirement that a specific number of phases of a clinical trial be conducted before a drug can be approved. If a phase 2 study is well-done and persuasive and can be interpreted as meeting safety and efficacy criteria, it can provide the basis for FDA approval. There is no absolute requirement for a phase 3 study.
-------------------------------------------------
CereSpir said to have started in early phase 3 studies, but everything is still at stage 2 - see the following link:
http://clinicaltrials.gov/ct2/results?term=CHF+5074
Therefore, I believe that they are updating and preparing everything necessary for the FDA ...
.
I feel and believe that $ 1 million or $ 10 million that ILNS will receive from Pfizer are just a drop of water in the sea ...
I think it's already been a merger between Intellect and CereSpir with CEO Dr. Chain.
I am convinced that they are waiting for approval from the FDA for CHF 5074 ...
Takeoff to $ 10 by 2014 ...
http://clinicaltrials.gov/ct2/results?term=CHF+5074
http://clinicaltrials.gov/ct2/show/NCT01602393?term=CHF+5074&rank=3
------------------------------------------------------------------
... “Chris has one of the most successful track records in developing drugs that receive FDA and EMA approval. CHF 5074 will benefit from Chris’ knowledge of and insight into what the regulatory bodies are seeking from clinical trials and marketing approval applications.” ...
http://www.cerespir.com/c/news/releases/011014.htm
... Upon receiving further input from the U.S. Food and Drug Administration, CereSpir anticipates initiating a Phase 3 clinical trial to determine if CHF 5074 has the potential to become the first therapy for people with ApoE4 genotype and amnestic Mild Cognitive Impairment (MCI). The Company’s ultimate goal is to start treating patients with CHF 5074 before amyloid plaques develop as a prevention strategy for Alzheimer’s disease....
http://www.cerespir.com/c/news/releases/110813.htm
... CereSpir is integrating the findings from Chiesi’s development work to finalize the Phase 3 clinical protocols in consultation with key opinion leaders in AD research and the U.S. Food and Drug Administration’s Special Protocol Assessment procedure. ...
http://www.cerespir.com/c/our-company/index.htm
.
Have I wrong to understand that the final verdict against Pfizer had to be from May 20 to 28?
What must still we wait?
Thanks ...
.
BUYING LEVELS
Traders buy before the news come
Investors buy after the news come
Big players buy after the stock over $ 1
Hedge Funds buy after the stock over $ 5
-
The Repackaging Plan ...
The repackaging plan usually involves a private equity company using leveraged loans from the outside to take a currently public company private by buying all of its outstanding stock. The buying firm's goal is to repackage the company and return it to the marketplace in an initial public offering (IPO).
The acquiring firm holds the company for a few years to avoid the watchful eyes of shareholders. This allows the acquiring company to repackage the company behind closed doors, making adjustments here and there and dressing it up. When this is done on a large scale, private firms can buy many companies at once in an attempt to diversify their risk among various industries. Once the acquired company is dressed up, it is offered back to the market as an IPO with some fanfare.
Those who stand to benefit from a deal like this are the original shareholders (if the offer price is greater than the market price), the company's employees (if the deal saves the company from failure) and the private equity firm that generates fees from the day the buyout process starts and holds a portion of the stock until it goes public again. Unfortunately, if no major changes are made to the company, it's a zero-sum game and the new shareholders get the same financials the old company had.
http://www.investopedia.com/articles/financial-theory/08/leveraged-buyouts.asp
( CereSpir + Intellect = CHF 5074 (phase 3) + Intellect pipeline + milestone VP20629 + milestone Ponezumab ).
Other companies in the OTC market, with fewer drugs in the pipeline, are valued from 2 to 10 dollars per share!
.
Correct link:
http://www.jefferson.edu/jeffnews/past/98/march/ovarian.html
Does not work:
www.jefferson.edu/jeffnews/past/98/march/ovarian.html - 6k - 2014-02-24
.
Jefferson Scientists' Results Raise Hopes for Ovarian Cancer Vaccine
Jefferson Medical College researchers have created what they believe may prove to be an effective ovarian cancer vaccine made from a patient's own cancer cells.
...
www.jefferson.edu/jeffnews/past/98/march/ovarian.html - 6k - 2014-02-24
------------------------------------------------------------------
Developing therapeutic cancer vaccines ...
Tumour-cell vaccines
Another treatment option is tumour-cell vaccines, which contain tumour cells obtained from the patient following surgery. These vaccines are intended to prevent disease recurrence in patients who have received prior treatment.
AVAX Technologies is developing a melanoma vaccine, which is marketed as MVax in Switzerland for the post-surgical treatment of stage III and IV malignant melanoma. The vaccine was developed using AC Vaccine technology licensed from the Thomas Jefferson University in the US, and consists of tumour cells conjugated to dinitrophenyl, a highly immunogenic hapten.
http://search.jefferson.edu/search?q=melanoma+vaccine&site=Jefferson&btnG=Search&entqr=0&entsp=a&sort=date%3AD%3AL%3Ad1&output=xml_no_dtd&client=jefferson&submit=GO&ud=1&oe=UTF-8&ie=UTF-8&proxystylesheet=jefferson
.
The main problem is the elapsed time (6 months) without any news.
Any Pharmaceutical Companies would take up to 3 months to do a merger, a sale or a partnership!
Probably, the work has been completed in the past months.
Now, everyone is waiting for the results of Ponezumab and VP20629.
Obviously, Pfizer and Shire want to evaluate the performance of products before signing the agreements ...
Otherwise, I cannot understand the reason for this long delay ... with Dr. Chain, Mr. Maza and Evli who continue to work (??!?)
Friedreich's ataxia VP20629 and Phase 1b
Status
ViroPharma has completed Phase 2 - enabling toxicology studies with VP 20629, and has initiated Phase 1b testing in patients with Friedreich's ataxia.
http://www.viropharma.com/pipeline/vp20629.aspx
---------------------------------------------
Meaning of Phase 1b:
- The Complete Phase Ib Trial Design Design
- An Approach for Getting to Phase II Faster
... Known as “the complete phase 1b,” the design streamlines phase 1 by testing various drug combinations in one trial with multiple arms running in parallel. This structure creates rapid accrual rates, substantial economies of scale and significant time savings for sponsors versus the traditional sequential approach. It also garners enthusiasm from investigators and patients, who ultimately gain greater potential for improved therapeutic benefits and care. ...
( read more )
http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design/
.
Today, I received a strange gift!
I wanted to be sure to buy more shares, and I offered $ 0.0055 per share.
To my surprise, they gave me the shares to $ 0.0051 ...
Probably, someone wants to keep this stock under sea level ...
I don't know who they are, and when they will finish playing downward!
.
Dr. Chain is primarily a financial engineer, and then he is a scientist - a doctor.
No one will know his poker cards ...
Somebody, 2,000 years ago said: Whoever believes in me, follow me ...
.
Nov. 26, 2013 (GLOBE NEWSWIRE)
CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease, announced today Richard Margolin, MD, has joined the Company as Vice President, Clinical Development. Dr. Margolin will lead CereSpir's Phase 3 program for CHF 5074, which includes two clinical trials anticipated to begin in 2014, and will report directly to Daniel G. Chain, PhD, Chairman, President and Chief Executive Officer. ........
http://globenewswire.com/news-release/2013/11/26/592577/10059519/en/CereSpir-Incorporated-Appoints-Richard-Margolin-MD-as-Vice-President-Clinical-Development.html
..................................................................................................
I hope that CereSpir bought Intellect, it will be a new and big Pharma in Alzheimer's field ...
.
2 - Itellect and Shire
Our pipeline
We focus our development resources on projects within our core therapeutic areas of Neuroscience, Rare Diseases, Gastrointestinal and Regenerative Medicine, as well as early development projects in additional therapeutic areas.
http://www.shire.com/shireplc/en/rd/pipeline
-----------------------------------------------------------------------------
Neuroscience
Shire unleashes potential for people affected by neurological disorders by creating holistic solutions to help them lead better lives. Neuroscience lies at the core of Shire’s global reputation today. We have built a world-leading ADHD portfolio and pipeline, supported by unrivalled expertise across development, commercial, reimbursement and pricing. We are committed to broadening Vyvanse’s potential across additional behavioral health indications including major depressive disorder, negative symptoms of schizophrenia, and binge eating disorder
Areas of interest are behavioural health disorders with a high level of unmet need that are served by specialist physicians. We are seeking licensing and partnering opportunities for differentiated products and technologies in the following disease areas:
1. Developmental behavioural disorders
• ADHD, autism, binge eating disorder, learning disabilities
2. Mood and related disorders
• Refractory or treatment-resistant depression; schizophrenia (negative symptoms); post-traumatic stress disorder
3. Disease-specific cognitive impairment (e.g schizophrenia, autism)
We have a broad interest in novel treatments in the above areas and have the flexibility that allows us to consider innovative partnerships and collaborations.
http://www.shire.com/shireplc/en/business/specialty-pharmaceuticals
.
INTELLECT and SHIRE - ( only VP20629 or more??? )
11 Nov 2013
... Additional value from ViroPharma’s other marketed products and pipeline.
... The acquisition also brings ViroPharma’s pipeline products to Shire, including two phase 2 products being investigated for infectious diseases: Maribavir (for the treatment of cytomegalovirus infection in transplant patients) and VP20621 (for the prevention of recurrent Clostridium difficile infection). Also in the ViroPharma pipeline are VP-20629 for Friedreich’s Ataxia, currently in phase 1, ...
http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=882
-------------------------------------------------------------------
07 Nov 2013
Shire Updates on Reorganisation Programme
Shire Pharmaceuticals today provides an update on its “One Shire” programme which is being implemented to ensure that the Company is simplified and optimally positioned to deliver its strategy and sustain its track record of high growth. As a part of this, Shire announces that it has initiated an employee consultation process at its site in Basingstoke.
Strategic priorities
Shire is a global specialty pharmaceutical company. It is focused on bringing innovative treatments to patients with unmet medical needs around the world.
Since May, Shire has been concentrating on its strategic priorities of growing sales of the existing portfolio, bringing new innovative treatments to market through both Research & Development (“R&D”) and business development, while driving greater efficiency within the business.
“One Shire”
As detailed previously, Shire has been implementing the “One Shire” reorganisation aimed at simplifying the business. Prior to this, Shire had three autonomous divisions, each with their own R&D, supply chain, technical operations and commercial infrastructures. These three divisions are being reorganised so they are one business, with much reduced overlap.
Pipeline prioritisation
The Company also announced recently that its product pipeline has been prioritised to focus on programmes that have the best chance of clinical and commercial success, to enable Shire to fulfil its strategy. This has resulted in a decision to focus the current early stage clinical investment primarily on rare diseases. To this end, the Company is proposing to discontinue a number of programmes outside of rare diseases. The cessation of these programmes, which have been carried out in Basingstoke, will result in a significant decrease in the amount of R&D conducted in Basingstoke. A small number of functional roles will also potentially be impacted. ...
http://www.shire.com/shireplc/en/investors/investorsnews/irshirenews?id=880
.
I sent an email to Mr. Maza two days ago.
I pointed out the lack of updates from about 5 months ...
I asked if Evli has completed its work or not.
I received notification of reading my email, but I have not received reply!
I believe that now it is delicate moment and he cannot give any answer ...
.
Strange coincidence of high volumes on the days of September 9 - 13, 2013, both for ILNS and VIROPHARMA.
For VIROPHARMA volumes can be attributed to news that follows below ...
For ILNS volumes can be attributed ... ??? ( have you valid reasons? )
It is advisable to superimpose the two graphs at 3 months ...
---------------------------------------------------------------
As reported in date 09/13/2013
Biopharmaceutical company ViroPharma Inc. (VPHM), has held discussions on a potential sale and is working with Goldman Sachs Group Inc. (GS) on a possible auction process, Bloomberg News reported Friday, citing people with knowledge of the process.
Sanofi (SNY) and Shire PLC (SHP.LN) are among those who have shown interest, Bloomberg reported.
Full story at: www.bloomberg.com/news/2013-09-13/viropharma-said-to-hire-goldman-amid-interest-from-sanofi-shire.html
http://ih.advfn.com/p.php?pid=nmona&article=59207947
.
Perhaps there are advances that we do not know.
However, I am assuming that SHINE is not VIROPHARMA and instead of paying milestones to ILNS, SHINE could buy the whole pipeline ILNS ... ( example, $ 500 million ).
.
Could SHIRE buy ILNS to $ 1 per share?
VP 20629 only worth about $ 100 million ...
Mr. Pray, where found it?
OPKO buy shares in the open market before make
any move ...
Thanks !
.
It is not enough the CereSpir updating?
Intellect and CereSpir are the same company with two different names for strategic reasons ...
.